128 related articles for article (PubMed ID: 19540938)
1. Immunosuppressive effect of angiotensin receptor blocker on stimulation of mice CTLs by angiotensin II.
Maeda A; Okazaki T; Inoue M; Kitazono T; Yamasaki M; Lemonnier FA; Ozaki S
Int Immunopharmacol; 2009 Sep; 9(10):1183-8. PubMed ID: 19540938
[TBL] [Abstract][Full Text] [Related]
2. Human immunodeficiency virus type 1 Nef epitopes recognized in HLA-A2 transgenic mice in response to DNA and peptide immunization.
Sandberg JK; Leandersson AC; Devito C; Kohleisen B; Erfle V; Achour A; Levi M; Schwartz S; Kärre K; Wahren B; Hinkula J
Virology; 2000 Jul; 273(1):112-9. PubMed ID: 10891413
[TBL] [Abstract][Full Text] [Related]
3. Regulation of antigen-specific CTL and Th1 cell activation through 5-Hydroxytryptamine 2A receptor.
Inoue M; Okazaki T; Kitazono T; Mizushima M; Omata M; Ozaki S
Int Immunopharmacol; 2011 Jan; 11(1):67-73. PubMed ID: 20971187
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin II type 2 receptors contribute to vascular responses in spontaneously hypertensive rats treated with angiotensin II type 1 receptor antagonists.
Cosentino F; Savoia C; De Paolis P; Francia P; Russo A; Maffei A; Venturelli V; Schiavoni M; Lembo G; Volpe M
Am J Hypertens; 2005 Apr; 18(4 Pt 1):493-9. PubMed ID: 15831358
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 partially protects renal tubular epithelial cells from the attack of CD8+ cytotoxic T cells.
Waeckerle-Men Y; Starke A; Wüthrich RP
Nephrol Dial Transplant; 2007 Jun; 22(6):1527-36. PubMed ID: 17339272
[TBL] [Abstract][Full Text] [Related]
6. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen.
Zaremba S; Barzaga E; Zhu M; Soares N; Tsang KY; Schlom J
Cancer Res; 1997 Oct; 57(20):4570-7. PubMed ID: 9377571
[TBL] [Abstract][Full Text] [Related]
7. Host-oriented peptide evaluation using whole blood assay for generating antigen-specific cytotoxic T lymphocytes.
Kawabuchi Y; Yamaguchi Y; Ohshita A; Minami K; Toge T
Anticancer Res; 2004; 24(2C):1193-200. PubMed ID: 15154646
[TBL] [Abstract][Full Text] [Related]
8. Primary T-cell and activated macrophage response associated with tumor protection using peptide/poly-N-acetyl glucosamine vaccination.
Maitre N; Brown JM; Demcheva M; Kelley JR; Lockett MA; Vournakis J; Cole DJ
Clin Cancer Res; 1999 May; 5(5):1173-82. PubMed ID: 10353754
[TBL] [Abstract][Full Text] [Related]
9. Development of a murine mutant Ras CD8+ CTL peptide epitope variant that possesses enhanced MHC class I binding and immunogenic properties.
Bristol JA; Schlom J; Abrams SI
J Immunol; 1998 Mar; 160(5):2433-41. PubMed ID: 9498787
[TBL] [Abstract][Full Text] [Related]
10. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
[TBL] [Abstract][Full Text] [Related]
11. Two types of anti-TL (thymus leukemia) CTL clones with distinct target specificities: differences in cytotoxic mechanisms and accessory molecule requirements.
Tsujimura K; Takahashi T; Iwase S; Matsudaira Y; Kaneko Y; Yagita H; Obata Y
J Immunol; 1998 Jun; 160(11):5253-61. PubMed ID: 9605121
[TBL] [Abstract][Full Text] [Related]
12. Vaccination with T cell receptor peptides primes anti-receptor cytotoxic T lymphocytes (CTL) and anergizes T cells specifically recognized by these CTL.
Kuhröber A; Schirmbeck R; Reimann J
Eur J Immunol; 1994 May; 24(5):1172-80. PubMed ID: 7514132
[TBL] [Abstract][Full Text] [Related]
13. The requirements for triggering of lysis by cytolytic T lymphocyte clones. II. Cyclosporin A inhibits TCR-mediated exocytosis by only selectively inhibits TCR-mediated lytic activity by cloned CTL.
Lancki DW; Kaper BP; Fitch FW
J Immunol; 1989 Jan; 142(2):416-24. PubMed ID: 2492047
[TBL] [Abstract][Full Text] [Related]
14. CD86 (B7-2) can function to drive MHC-restricted antigen-specific CTL responses in vivo.
Agadjanyan MG; Kim JJ; Trivedi N; Wilson DM; Monzavi-Karbassi B; Morrison LD; Nottingham LK; Dentchev T; Tsai A; Dang K; Chalian AA; Maldonado MA; Williams WV; Weiner DB
J Immunol; 1999 Mar; 162(6):3417-27. PubMed ID: 10092797
[TBL] [Abstract][Full Text] [Related]
15. RPE cells resist bystander killing by CTLs, but are highly susceptible to antigen-dependent CTL killing.
Gregerson DS; Lew KL; McPherson SW; Heuss ND; Ferrington DA
Invest Ophthalmol Vis Sci; 2006 Dec; 47(12):5385-94. PubMed ID: 17122128
[TBL] [Abstract][Full Text] [Related]
16. Generation of IL-2-dependent cytolytic T lymphocytes (CTLs) with altered TCR responses derived from antigen-dependent CTL clones.
Gullo CA; Esser MT; Fuller CL; Lam Braciale V
J Immunol; 1999 Jun; 162(11):6466-72. PubMed ID: 10352261
[TBL] [Abstract][Full Text] [Related]
17. Studies on the induction and expression of T cell-mediated immunity. XIV. Antigen-nonspecific oxidation-dependent cellular cytotoxicity (ODCC) mediated by sodium periodate oxidation of cytotoxic T lymphocytes.
Fan J; Bonavida B
J Immunol; 1983 Sep; 131(3):1426-32. PubMed ID: 6193189
[TBL] [Abstract][Full Text] [Related]
18. Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy.
Machlenkin A; Paz A; Bar Haim E; Goldberger O; Finkel E; Tirosh B; Volovitz I; Vadai E; Lugassy G; Cytron S; Lemonnier F; Tzehoval E; Eisenbach L
Cancer Res; 2005 Jul; 65(14):6435-42. PubMed ID: 16024648
[TBL] [Abstract][Full Text] [Related]
19. Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide.
Correale P; Walmsley K; Zaremba S; Zhu M; Schlom J; Tsang KY
J Immunol; 1998 Sep; 161(6):3186-94. PubMed ID: 9743387
[TBL] [Abstract][Full Text] [Related]
20. Losartan inhibits LPS-induced inflammatory signaling through a PPARgamma-dependent mechanism in human THP-1 macrophages.
An J; Nakajima T; Kuba K; Kimura A
Hypertens Res; 2010 Aug; 33(8):831-5. PubMed ID: 20505677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]